Legal Opinion
Norwich Pharmaceuticals, Inc. v. Becerra
District Court, District of Columbia
Decided November 1, 2023No. Civil Action No. 2023-1611Published
1Opinion of the Court
UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA NORWICH PHARMACEUTICALS, INC., Plaintiff, Vv. Civil Action No. 23-1611 (RDM) XAVIER BECERRA, Secretary of Health and Human Services, etal, Defendants. MEMORANDUM OPINION Battles over the entry of generic drugs to market are often hard fought, particularly in cases involving brand-named drugs with annual sales that substantially exceed $1 billion. See Dkt. 1 at 11 (Compl. § 41). This is a case in point. Defendant-Intervenor Salix Pharmaceuticals, Inc. (“Salix”) currently markets rifaximin (under the brand name Xifaxan) for the treatment…
2Cases cited36 opinions
- Ashcroft v. IqbalSupreme Court of the United States · 2009
- Bell Atlantic Corp. v. TwomblySupreme Court of the United States · 2007
- Winter v. Natural Resources Defense Council, Inc.Supreme Court of the United States · 2008
- Citizens to Preserve Overton Park, Inc. v. VolpeSupreme Court of the United States · 1971
- Dolly Kyle Browning and Direct Outstanding Creations Corporation v. William Jefferson ClintonCourt of Appeals for the D.C. Circuit · 2002
31 more not listed; retrieve them via the Exa API.